Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonMark Ainsworth, Christopher J. Groves, Stuart Cox et al.|The Lancet Infectious Diseases|2020Cited by 405
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling studyDevin Razavi‐Shearer, Ivane Gamkrelidze, Calvin Q. Pan et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 399
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al.|The Lancet|2021Cited by 310
The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2Angelos Hatzakis, E. Nurmukhametova, Vladimir Chulanov et al.|Journal of Viral Hepatitis|2015Cited by 125
Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2V A Saraswat, N. Mamonova, Suzanne Norris et al.|Journal of Viral Hepatitis|2015Cited by 93